Search results for "Thymus Neoplasms"

showing 6 items of 16 documents

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

2014

Abstract Late-onset myasthenia gravis (LOMG) has become the largest MG subgroup, but the underlying pathogenetic mechanisms remain mysterious. Among the few etiological clues are the almost unique serologic parallels between LOMG and thymoma-associated MG (TAMG), notably autoantibodies against acetylcholine receptors, titin, ryanodine receptor, type I interferons or IL-12. This is why we checked LOMG patients for two further peculiar features of TAMG – its associations with the CTLA4 high/gain-of-function  +49A/A genotype and with increased thymic export of naive T cells into the blood, possibly after defective negative selection in AIRE-deficient thymomas. We analyzed genomic DNA from 116 …

Malemedicine.medical_specialtyGenotypeThymomaT-LymphocytesImmunologyDNA Mutational AnalysisRecent Thymic EmigrantLate onsetCell CountThymus GlandBiologyPeripheral blood mononuclear cellWhite PeopleGene FrequencyInternal medicineGenotypeMyasthenia GravismedicineImmune ToleranceImmunology and AllergyHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGenetic Association StudiesAgedPeripheral tolerance inductionAged 80 and overPolymorphism GeneticThymocytesT-cell receptor excision circlesAutoantibodyCell DifferentiationThymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyFemaleJournal of autoimmunity
researchProduct

Minimal manifestation status and prednisone withdrawal in the MGTX trial

2020

ObjectiveTo examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG).MethodsThis study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody–positive MG without thymoma. Patients were randomized 1:1 to thymectomy plus prednisone vs prednisone alone. Participants were age 18–65 years at enr…

Malemedicine.medical_treatmentAzathioprinelaw.invention0302 clinical medicineRandomized controlled trialPrednisonelawMedicineSingle-Blind Method030212 general & internal medicineYoung adultMiddle AgedThymectomyCombined Modality TherapySubstance Withdrawal Syndrome3. Good healthSettore MED/26 - NEUROLOGIA6.1 PharmaceuticalsAnesthesiaadolescent; adult; animals; combined modality therapy; female; humans; immunosuppressive agents; male; middle aged; myasthenia gravis; prednisone; rats; single-blind method; substance withdrawal syndrome; thymoma; thymus neoplasms; young adult; thymectomyCognitive SciencesFemaleImmunosuppressive Agentsmedicine.drugAdultThymomaAdolescentThymomaClinical Trials and Supportive ActivitiesClinical SciencesMGTX study groupAutoimmune DiseaseArticleYoung Adult03 medical and health sciencesRare DiseasesClinical ResearchMyasthenia GravisPost-hoc analysisAnimalsHumansNeurology & Neurosurgerybusiness.industryNeurosciencesEvaluation of treatments and therapeutic interventionsThymus Neoplasmsmedicine.diseaseMyasthenia gravisRatsThymectomyPrednisoneNeurology (clinical)business030217 neurology & neurosurgeryNeurology
researchProduct

The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

2022

Abstract This overview of the fifth edition of the WHO classification of thymic epithelial tumors (including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]), mediastinal germ cell tumors, and mesenchymal neoplasms aims to (1) list established and new tumor entities and subtypes and (2) focus on diagnostic, molecular, and conceptual advances since publication of the fourth edition in 2015. Diagnostic advances are best exemplified by the immunohistochemical characterization of adenocarcinomas and the recognition of genetic translocations in metaplastic thymomas, rare B2 and B3 thymomas, and hyalinizing clear cell carcinomas. Advancements at the molecular and tumor biolog…

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsThymomaThymomaAdenocarcinomaNeuroendocrine tumorsWorld Health OrganizationThymic carcinoma03 medical and health sciences0302 clinical medicineGerm cell tumormedicineHumansGerm cell tumor; NET G3; Thymic carcinoma; Thymic neuroendocrine tumor; Thymoma; WHO classificationThymic carcinoma030304 developmental biologyWHO classification0303 health sciencesbusiness.industryMesenchymal stem cellMediastinumMediastinumThymus Neoplasmsmedicine.disease3. Good healthThymic neuroendocrine tumorGerm Cellsmedicine.anatomical_structureOncology030220 oncology & carcinogenesisGerm cell tumorsNET G3businessClear cellGerm cellJournal of Thoracic Oncology
researchProduct

The Autoimmune Regulator AIRE in Thymoma Biology: Autoimmunity and Beyond

2010

Thymomas are tumors of thymic epithelial cells. They associate more often than any other human tumors with various autoimmune diseases; myasthenia gravis is the commonest, occurring in 10-50% of thymoma patients, depending on the World Health Organization-defined histologic subtype. Most thymomas generate many polyclonal maturing T lymphocytes but in disorganized microenvironments Failure to induce self-tolerance may be a key factor leading to the export of potentially autoreactive CD4 progeny, thus predisposing to autoimmune diseases. Normally, the master Autoimmune Regulator promotes expression of peripheral tissue-restricted antigens such as insulin by medullary thymic epithelial cells a…

Pulmonary and Respiratory MedicineThymomaThymomamedicine.medical_treatmentAutoimmunitymedicine.disease_causeWorld healthAutoimmune DiseasesAutoimmunityAntigenAIREhemic and lymphatic diseasesAPS-1HumansMedicineMyasthenia gravisbusiness.industryInsulinThymus NeoplasmsAutoimmune regulatormedicine.diseaseMyasthenia gravisOncologyImmunologybusinessAPECEDTranscription FactorsJournal of Thoracic Oncology
researchProduct

Bilateral single-port thoracoscopic extended thymectomy for management of thymoma and myasthenia gravis: Case report

2016

Background Video-assisted thoracoscopy is become a widely accepted approach for the resection of anterior mediastinal masses, including thymoma. The current trend is to reduce the number of ports and minimize the length of incisions to further decrease postoperative pain, chest wall paresthesia, and length of hospitalization. Herein, we reported an extended resection of thymoma in a patient with myasthenia gravis through an uniportal bilateral thoracoscopic approach. Case presentation A 74 years old woman with myasthenia gravis was referred to our attention for management of a 3.5 cm, well capsulate, thymoma. All laboratory and cardio-pulmonary tests were within normal; thus, she was schedu…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyThymomaThymomamedicine.medical_treatmentlcsh:SurgeryMyasthenia gravi030204 cardiovascular system & hematologylcsh:RD78.3-87.303 medical and health sciences0302 clinical medicineCase reportmedicineThoracoscopyIntubationHumansGeneral anaesthesiaThymus NeoplasmMyasthenia gravisUniportalAgedmedicine.diagnostic_testbusiness.industryThoracic Surgery Video-AssistedThoracoscopyGeneral MedicineThymus Neoplasmslcsh:RD1-811Bilateralmedicine.diseaseThymectomyMyasthenia gravisSurgeryDissectionSettore MED/18 - Chirurgia Generalemedicine.anatomical_structure030228 respiratory systemCardiothoracic surgerylcsh:AnesthesiologyFemaleSurgeryIntercostal spacebusinessCardiology and Cardiovascular MedicineHuman
researchProduct

Clinical characteristics and outcomes of thymoma-associated myasthenia gravis

2021

[Background and purpose] Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.

medicine.medical_specialtyThymomaThymomaEnfermedad del sistema nerviosoMiastenia gravischemical and pharmacologic phenomenaGastroenterology03 medical and health sciences0302 clinical medicineDisease severityRecurrenceInternal medicinehemic and lymphatic diseasesMyasthenia GravismedicineHumansIn patient030212 general & internal medicineneoplasmsNeurologíaMyasthenia gravisRetrospective Studiesbusiness.industryHazard ratioOdds ratioThymus Neoplasmsthymomamedicine.diseaseThymectomyPrognosisConfidence intervalMyasthenia gravisThymomEfectos fisiológicossurgical procedures operativeNeurologyMulticenter studySignos y síntomasNeurology (clinical)Neoplasm Recurrence LocalbusinessTimoma030217 neurology & neurosurgery
researchProduct